3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Other solid neoplasm
1
Other hematologic neoplasm
1
Myeloid
1
Gastrointestinal
1
Dermatologic
1
CNS
1
Conditions
Carcinoma, Non-Small-Cell Lung
4
Pancreatic Neoplasms
2
Myelodysplastic Syndromes
2
Leukemia, Myeloid, Acute
2
Triple Negative Breast Neoplasms
1
Mesothelioma, Malignant
1
Melanoma
1
Inflammatory Breast Neoplasms
1
Glioblastoma
1
COVID-19
1
Adenocarcinoma of Lung
1
Interventions
Pemetrexed
15
Cisplatin
13
pembrolizumab
6
Platinum
4
1,2-diaminocyclohexaneplatinum II citrate
4
cediranib
3
Radiotherapy
3
Gemcitabine
3
Carboplatin
3
amatuximab
2
Radiotherapy, Intensity-Modulated
2
Radiation
2
Everolimus
2
Drug Therapy
2
Cyclophosphamide
2
tumor necrosis factor-alpha, CNGRC fusion protein, human
1
tremelimumab
1
sodium thiosulfate
1
sargramostim
1
nintedanib
1
napabucasin
1
methoxyamine
1
liposomal doxorubicin
1
incomplete Freund's adjuvant
1
fresolimumab
1
durvalumab
1
defactinib
1
cixutumumab
1
bintrafusp alfa protein, human
1
bemcentinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
Mesothelioma, Malignant
×
bemcentinib
×
Clear all
NCT06469138
2025-01-29
8479217
BerGenBio ASA
Phase 1
Completed
6 enrolled
17 charts